Background {#Sec1}
==========

Rationale {#Sec2}
---------

Persistent infection with human papillomavirus (HPV) strains 16 and 18 can cause cervical and other cancers \[[@CR1]\]. The prevalence of these strains can vary by socioeconomic factors, including geography and ethnicity \[[@CR2], [@CR3]\]. There are well-documented inequities in cancer prevention, disease burden, and subsequent treatment, for First Nation (FN), Inuit, and Métis peoples in Canada \[[@CR2], [@CR4]--[@CR10]\]. While acknowledging that there is heterogeneity across and within each of these peoples, we respectfully refer to them 'Indigenous unless otherwise specified. The prevalence of HPV infection and cervical cancer is significantly higher \[[@CR11]--[@CR23]\] and HPV vaccination rates lower among Indigenous peoples \[[@CR23]\]. This inequity exists despite the availability of vaccines with demonstrated safety profiles and efficacy, and funded vaccination programs \[[@CR24]--[@CR26]\].

Enhancing HPV vaccination is a potentially high-impact, low-cost opportunity for cancer risk reduction among Indigenous peoples. As part of a tri-phase study in First Nations people to (1) establish baseline HPV vaccination rates, (2) systematically identify and validate the barriers and supports to HPV vaccination, and (3) comprehensively map documented and reported supports and barriers to HPV vaccination to develop a theory-informed, context-appropriate knowledge translation intervention, this synthesis aims to identify documented barriers, supports, and intervention strategies for HPV vaccination in Canadian and global Indigenous populations.

Vaccine acceptability, hesitancy, and uptake {#Sec3}
--------------------------------------------

Despite its success as a public health intervention \[[@CR27]--[@CR34]\], vaccination in many countries still falls short of levels needed to ensure community protection \[[@CR30], [@CR35]--[@CR37]\]. Even where vaccination rates are high, ongoing acceptance remains a vulnerability \[[@CR35]\], as evidenced by significant variability among different groups within high vaccine-coverage countries \[[@CR30], [@CR37]\]. Measuring vaccination rates can be challenging, requiring different metrics to quantify impact. "Vaccine coverage" (e.g., the proportion of the target population who have received the vaccine) is the typical population-level measure of protection \[[@CR30], [@CR37]--[@CR39]\], while "vaccine acceptability" and "uptake" are more common, individual-level measures. "Vaccine acceptability" reflects individuals' willingness to accept vaccination, typically assessed as attitudes, beliefs, and/or intentions \[[@CR40]\]. A more commonly used term, "vaccine hesitancy", refers to a delay in acceptance or refusal of vaccines despite the availability of vaccine services \[[@CR41]\]. "Vaccine uptake" reflects the behavior of getting vaccinated \[[@CR37]\]. Understanding the barriers and supports to vaccine acceptability/hesitancy, moving from acceptance to uptake, and uptake from multiple perspectives (e.g., recipient, parents/guardians, health care providers, policy makers) \[[@CR25]\], is a critical first step to tailoring strategies to enhance vaccination \[[@CR37], [@CR42]\].

Barriers and supports to vaccine acceptability and uptake {#Sec4}
---------------------------------------------------------

General barriers and supports to vaccine acceptability and uptake of childhood vaccines have been documented \[[@CR41], [@CR43], [@CR44]\]. The most common factors include socio-demographic characteristics (e.g., race, marital status, maternal age/education, family size/income) \[[@CR45]--[@CR50]\], knowledge and beliefs (e.g. fear of side effects, lack of perceived susceptibility to disease) \[[@CR45], [@CR46], [@CR49], [@CR50]\], trust in the establishment (e.g., trust in the medical community or government) \[[@CR46], [@CR49]--[@CR51]\], social and cultural norms (e.g., family, religious, or community influences) \[[@CR45], [@CR49]\], worldview regarding health (e.g., preference for natural interventions) \[[@CR45], [@CR49]\], healthcare provider influence (e.g., provider recommendations and/or knowledge) \[[@CR49], [@CR50]\], competing priorities (e.g., social support, child care) \[[@CR50], [@CR52], [@CR53]\], concern about vaccination processes (e.g., vaccination pain or needles) \[[@CR46], [@CR49]--[@CR51]\], and access to services (e.g., clinic hours and location) \[[@CR48]--[@CR50]\]. Some of these factors are more prominent in specific sub-populations and/or for specific vaccines \[[@CR30], [@CR40]\].

HPV vaccine-specific barriers, supports, and effective interventions {#Sec5}
--------------------------------------------------------------------

In Canada, the HPV vaccine was introduced into national and regional vaccination programs targeting pre-adolescents in school settings \[[@CR54]\], to prevent cancers caused by HPV \[[@CR55], [@CR56]\]. Vaccines preventing HPV infection demonstrate long-term effectiveness and acceptable safety profiles \[[@CR24]\]. However, a number of issues specific to the HPV vaccine influence its acceptability and uptake in the general population; these factors are well described in systematic reviews \[[@CR25], [@CR26], [@CR57]--[@CR61]\] and include knowledge and perceived risk of HPV disease, misinformation about vaccine safety, cost, misperceptions that the vaccine induces sexual promiscuity, and multi-dose vaccine series delivery. Additional challenges in the school setting include the information and consent process, vaccination setting, and student anxiety regarding privacy and pain during vaccination \[[@CR62]\]. In high-income countries, access to and receipt of the HPV vaccine is determined by factors that influence policy makers, health care professionals, and parental decision-making, including financial constraints, social norms and values concerning sexual activity, and trust in vaccination programs and health care providers \[[@CR61]\]. Further, barriers, and supports may be context-specific; for example, access to HPV vaccine may be facilitated by universal coverage health care systems or hindered by parents' cultural or religious perceptions about sexual activity \[[@CR61]\]. Much of the literature reports barriers and supports to HPV vaccine acceptability, as reported by parents, health care providers, and policy makers \[[@CR25]\], rather than vaccine recipients. This gap in self-reported data hinders effective, evidence- and theory-informed intervention mapping \[[@CR63]\].

A recent systematic review \[[@CR25]\] summarized the nature and frequency of adolescent females' self-reported barriers to HPV vaccination. These factors included cost, perceived lack of need, concerns about safety and side effects, perceived efficacy, perceived relative benefit, vaccination logistics, fear of needles, vaccine novelty, perception that sexual inactivity precludes the need for vaccination, negative physician-related recommendations, social norms, inability to discuss the vaccine with parents, lack of awareness or information, anti-vaccination views, subjective norms, pregnancy (or trying to conceive), self-efficacy, mistrust of pharmaceutical companies, and the perception that alternative strategies are available. Cost and the perception that HPV vaccination leads to increased sexual activity were previously identified as vaccination barriers \[[@CR60]\]. Adolescent females' self-reported supports to HPV vaccination included perceived benefit, positive health care provider recommendations, social norms, parental endorsement, perceived risk, cost-free access, subjective norms, perceived severity, positive attitude toward vaccine or reported personal importance of vaccine, self-efficacy, and vaccine efficacy \[[@CR25], [@CR60]\].

Although a recent systematic review reported a lack of consistency and detailed reporting of interventions to increase HPV vaccine uptake \[[@CR64]\], it found that the nature and magnitude of effect for national and international strategies (e.g., single and multifaceted behavioral \[targeted at patient, provider and patient-provider\] and environmental \[local and national level policies\]) were documented. It also revealed that environmental interventions (e.g., school-based vaccine administration) achieved the highest vaccination rates, but noted a lack of data for differentiating subpopulations. The need was underscored for specific strategies and interventions to target underserved populations, including Indigenous youth \[[@CR64], [@CR65]\].

Barriers and supports to HPV vaccine acceptability and uptake in indigenous peoples {#Sec6}
-----------------------------------------------------------------------------------

HPV vaccine coverage levels in the general population of pre-adolescents may hide sub-populations with lower coverage, including Indigenous peoples who are known to have higher HPV infection rates \[[@CR2], [@CR11], [@CR66]\], lower cervical cancer screening rates \[[@CR13], [@CR14], [@CR67]\], higher rates of invasive cervical cancer \[[@CR15], [@CR68]\], higher rates of cervical cancer-related hospitalizations \[[@CR16]\], and lower rates of cervical cancer survival \[[@CR17], [@CR18], [@CR69]\]. There is a paucity of data on HPV vaccination coverage in Indigenous peoples; however, it is well known that other childhood vaccinations in these groups are typically below that of the general population \[[@CR52], [@CR70]--[@CR76]\]. Ongoing work in Canada \[[@CR77]\] and Australia \[[@CR78]\] strives to accurately track coverage levels, but an important companion to this work is a more detailed understanding of the barriers and supports to vaccination in Indigenous peoples. Moreover, generic interventions aimed at improving vaccine uptake in the general population of pre-adolescent children may require modifications or redesign for Indigenous peoples \[[@CR79], [@CR80]\], particularly given the multijurisdictional complexities in health services delivery for those living on reserve. In addition, context and pragmatics (e.g., differing HPV vaccination programs in municipal schools versus on-reserve schools) may impact coverage levels \[[@CR81]\].

The evidence compiled thus far on the barriers, supports, and interventions for HPV vaccination reveals considerable gaps in data for Indigenous peoples. Even so, any evidence on vaccination in this population may provide important guidance for future work. To our knowledge, this will be the first synthesis of the barriers, supports, and interventions for improving vaccination and HPV vaccination in Indigenous peoples. Synthesis-level knowledge in this area is expected to support Indigenous peoples, researchers, clinicians, policy makers, and communities in their efforts to ameliorate well-documented and disproportionate burdens of disease that persist in Indigenous populations worldwide.

Methods/design {#Sec7}
==============

Aims {#Sec8}
----

Because we anticipate only a small number of relevant studies on HPV vaccination to emerge from the search, we will employ a broad search strategy to capture literature related to both HPV vaccination and vaccination in general among Indigenous peoples in Canada and globally. This systematic review will locate, gather, and critically appraise the global literature in Indigenous peoples \[[@CR77]\], relating to (a) documented barriers and supports to vaccination and specifically HPV vaccination (V/HPV-V) and (b) interventions to increase acceptability and uptake or reduce hesitancy of V/HPV-V.

The design of this mixed methods \[[@CR82]--[@CR84]\] systematic review protocol and search strategy was guided by the Cochrane Handbook for Systematic Reviews \[[@CR85]\], the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) \[[@CR86]\] and protocols (PRISMA-P) \[[@CR87]\], and ENTREQ \[[@CR88]\] reporting guidelines. Because our study will generate both quantitative and qualitative data, we propose segregated analyses on each data set \[[@CR89]\]; qualitative data will be managed using NVivo10 \[[@CR90]\] and quantitative data will be captured and managed in MS Excel and analyzed using STATA v13.1 \[[@CR91]\]. This study protocol was registered with the International Prospective Register of Systematic Reviews on March 1, 2017 (PROSPERO CRD42017048844). Any protocol amendments will be discussed as the review proceeds and documented using a protocol addendum in the final report \[[@CR92], [@CR93]\] (see Additional file [1](#MOESM1){ref-type="media"}).

Research questions {#Sec9}
------------------

Primary questions of interest are:What are the documented barriers and supports to V/HPV-V, in Canadian Indigenous and global Indigenous peoples?What are the documented interventions to increase acceptability and uptake or reduce hesitancy of V/HPV-V, in Canadian Indigenous and global Indigenous peoples?

Secondary questions of interest are:3.What are the documented barriers and supports to V/HPV-V, in youth (\< 18 years) within Canadian Indigenous and global Indigenous peoples?4.What are the documented interventions to increase acceptability and uptake or reduce hesitancy of V/HPV-V, in youth (\< 18 years) within Canadian Indigenous and global Indigenous peoples?

Eligibility criteria {#Sec10}
--------------------

We will include studies that involve global Indigenous peoples, including First Nations, Inuit, and Métis (Canada), American Indians and Alaskan Natives (USA), and Indigenous peoples in other countries including, but not limited to, China, South Asia, former Soviet Union, Southeast Asia, South America, Africa, Central America/Mexico, Arabia, Japan and the Pacific Islands, Australia, New Zealand, Greenland, and Scandinavia \[[@CR69], [@CR94], [@CR95]\]. Study participants may include vaccine recipients, youth, parents, grandparents, guardians, and Elders and/or knowledge holders, health care providers, policy-makers, decision-makers, and community leaders, without restricting by sex or age. Draft inclusion-exclusion criteria were developed (Table [1](#Tab1){ref-type="table"}) and refined using key articles identified from preliminary search findings. Eligible studies will (a) include global Indigenous peoples *and* (b) discuss barriers or supports *and/or* interventions to improve uptake/acceptability or to reduce vaccine hesitancy for V/HPV-V. Studies will be excluded if they do not (a) include global Indigenous peoples or include subpopulation(s) of one or more global Indigenous peoples comprising more than 50% of study participants, or for which separate analyses for global Indigenous peoples or subpopulation(s) are not presented; (b) discuss barriers, supports or interventions for enhancing acceptability or uptake or reducing hesitancy for V/HPV-V; (c) report extractable data; or (d) report original research.Table 1Study inclusion and exclusion criteriaInclusion criteriaExclusion criteriaGlobal Indigenous peoples (including First Nations, Inuit, and Métis (Canada), American Indians and Alaskan Natives (USA), and Indigenous peoples in other countries including, but not limited to, China, South Asia, former Soviet Union, Southeast Asia, South America, Africa, Central America/Mexico, Arabia, Japan and the Pacific Islands, Australia, New Zealand, Greenland and Scandinavia) \[[@CR69], [@CR94]\] and participants may include vaccine recipients, youth, parents, grandparents, guardians, Elders and/or knowledge holders, health care providers, policy−/decision-makers, and community leaders, without restriction on gender or age,\
ANDStudies that do not include global Indigenous peoples or in which one or more global Indigenous peoples comprise less than 50% of the study participants\
OR\
Studies that do not discuss barriers or supports to vaccination or HPV vaccination\
AND/OR\
Studies that do not discuss vaccination interventions, or HPV vaccination interventions or enhancing the acceptability or uptake of vaccination or HPV vaccination, or reducing vaccine or HPV vaccine hesitancy\
OR\
Studies lacking extractable data (i.e., policy papers or papers with no data)\
ORStudies discuss barriers or supports to vaccination or HPV vaccination\
AND/ORNon-original researchStudies discuss vaccination interventions to increase acceptability or uptake of vaccination or HPV vaccination, or to reduce vaccine or HPV vaccine hesitancy

Outcome measures {#Sec11}
----------------

Primary outcomes are documented barriers or supports *or* interventions that increase or enhance acceptability/uptake *or* interventions to reduce hesitancy for V/HPV-V. Secondary outcomes will investigate these same factors, specific to youth (\< 18 years) in Canadian and global Indigenous peoples. For this review, we define barriers as *single or multilevel factors that are negatively associated with, or hinder the acceptability or uptake of V/HPV-V or increase hesitancy.* Supports include *single or multilevel factors that are positively associated with, or enhance the acceptability and uptake of V/HPV-V or reduce hesitancy*. Vaccination acceptability is defined as *individuals' willingness to accept vaccination (typically measured by assessing attitudes, beliefs, and/or intention to be vaccinated)* and vaccine uptake is defined as *the behavior of getting vaccinated* \[[@CR40]\]. Vaccine hesitancy refers to a *delay in acceptance or refusal of vaccines despite the availability of such services* \[[@CR41]\]. In order to optimize the capture of literature, vaccination intervention is defined as *a singular or multilevel, simple and/or complex strategy(ies) used in the design or execution of vaccination or used to increase or enhance vaccine acceptability, uptake or to reduce vaccine hesitancy.* Vaccination is defined as *the act of introducing a vaccine into the body to produce immunity to a specific disease* \[[@CR96]\]. Study outcomes will be segregated into three main variable groups: study characteristics, barriers and supports, and vaccination interventions (acceptability, uptake, hesitancy).

Study type {#Sec12}
----------

All study designs meeting inclusion criteria will be considered, without restricting by language, location, or data type (i.e., qualitative, quantitative, and mixed methods studies are eligible).

Data sources and search strategy {#Sec13}
--------------------------------

A comprehensive search of the literature will use an a priori search strategy (draft MEDLINE search strategy in Table [1](#Tab1){ref-type="table"}) comprised of key words and controlled vocabulary terms (Medical Subject Headings or MeSH terms). The core search strategy was developed in MEDLINE, in partnership with an academic librarian (HG) and submitted to a second academic librarian (YL) for independent peer review using the Peer Review of Electronic Search Strategies (PRESS) checklist \[[@CR97]\]. PRESS feedback was integrated and the finalized strategy translated for use with the remaining databases. We will search several electronic databases (MEDLINE, CINAHL, EMBASE, Web of Science, PsycINFO, Global Index Medicus \[LILACS and Western Pacific Region Index Medicus\], Cochrane Database of Systematic Reviews, Joanna Briggs Institute Database, Scopus, Bibliography of Native North Americans, University of New Mexico Native Health Database, ProQuest Dissertations, Australian Indigenous HealthInfoNet) from first date of inception to September 2017, without restrictions (Table [2](#Tab2){ref-type="table"}).Table 2Draft search strategyDatabases: Ovid MEDLINE(R) Epub Ahdead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to present (Feb 22, 2017)The core search around the concepts of HPV and vaccination is as follows:1. exp. Papillomavirus Infections/2. exp. Vaccination/3. (hpv or human papilloma\* or vaccin\* or immuniz\*or immunis\*).kw,tw.4. 1 or 2 or 3To identify studies involving Canadian indigenous populations, we applied a filter developed by health librarians at the University of Alberta \[[@CR109]\] to identify Canadian indigenous populations to the above search.We also ran this search against subject headings and keywords to identify studies related to selected global indigenous populations, as follows:Databases: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to present (Feb 22, 2017)1. exp. Papillomavirus Infections/2. exp. Vaccination/3. (hpv or human papilloma\* or vaccin\* or immuniz\* or immunis\*).kf,tw.4. 1 or 2 or 35. exp. american native continental ancestry group/ or exp. oceanic ancestry group/6. exp. Health Services, Indigenous/7. exp. United States Indian Health Service/8. (aborigin\* or Alaska\* Native\* or American Indian\* or Amerindian\* or Eskimo\* or community-based participatory or indigenous or Inuit\* or Maori or Métis or Native American\* or Native Hawaiian\* or native people\* or tribe\* or tribal or Pacific Islander\* or Torres Strait Islander\*).kf,tw.9. 5 or 6 or 7 or 810. 4 and 9\*denotes *wildcard* symbol in the search syntax. The wildcard broadens the search strategy by capturing the denoted word stem and all other derivatives beginning with the same letters

Gray literature search strategy {#Sec14}
-------------------------------

A search will be employed to identify original research that is not reported in peer-reviewed journal articles. The search and Level 1 screening process will be conducted concurrently, with two researchers searching a pre-defined group of government, agency, and Canadian and global Indigenous websites to locate relevant gray literature (Table [3](#Tab3){ref-type="table"}). Combinations of the following combinations will be used: (1) Indigenous or Aboriginal or Indian, and (2) Vaccine or Vaccination or Immunization or Immunize or Immunization or Immunize or HPV or Human papillomavirus. Terms will be combined using "and" or "&". Websites and resources that pertain to (1) Indigenous populations and (2) discuss barriers/supports or interventions to improve vaccination or HPV vaccination will be retained for screening. The title, URL, and data accessed for all websites/resources identified through this search will be entered into an Excel spreadsheet. Questionable resources will be retained for screening. All websites/resources identified in the search will be screened to determine if they meet the inclusion criteria (Table [1](#Tab1){ref-type="table"}). Bibliographic searches will be conducted for all included studies and additional papers identified. We will also contact known provincial, national, and international experts working in this area (e.g., H. O'Donnell \[Australia\], S. Moore \[Australia\], R. Bednarczyk \[United States\]) for advice on relevant published and unpublished works.Table 3Gray literature -- website search planGray literature resource nameURLHealth Sciences Online (HSO)[www.hso.info](http://www.hso.info)OAISter<http://oaister.worldcat.org>/International Network in Indigenous Health Knowledge and Development (INIHKD)<http://www.inihkd.org>Canadian Electronic Library's Public Documents Collection (previously the Canadian Health Research Collection)<http://www.canadianelectroniclibrary.ca/Default.aspx>Center for World Indigenous Studies<http://cwis.org>/Circumpolar Health Database<http://www.aina.ucalgary.ca/chbd/>Health Info Net<http://www.healthinfonet.ecu.edu.au/key-resources/bibliography>Metis Health Database<https://www.ccnsa-nccah.ca/en/>Native Indigenous Studies Portal<http://iportal.usask.ca/>Public Health Agency of Canada (PHAC)<http://www.phac-aspc.gc.ca/publicat/cdic-mcbc/index-eng.php?utm_source=subscription_list&utm_medium=email_eng&utm_content=index&utm_campaign=CDIC_32_2>First Nations Development Institute[www.firstnations.org](http://www.firstnations.org)Active Circle[www.activecircle.ca/en](http://www.activecircle.ca/en)Aboriginal Affairs and Northern Development (Government of Canada)<https://www.aadnc-aandc.gc.ca/eng/1100100010002/1100100010021>Centre for Indigenous Peoples' Nutrition and Environment (CINE)<https://www.mcgill.ca/cine/centre-indigenous-peoples-nutrition-and-environment-cine>First Nations Environmental Health Innovation Network<http://www.fnehin.ca>Assembly of First Nations<http://www.afn.ca/Assembly_of_First_Nations.htm>First Nations and Inuit Health Branch (Government of Canada -- Health Canada)<http://www.hc-sc.gc.ca/fniah-spnia/index-eng.php>National Collaborating Centre for Aboriginal Health (NCCAH) (Government of Canada)[http://www.nccah-ccnsa.ca/en/](http://www.nccah-ccnsa.ca/en)National Aboriginal Health Organization (NAHO) (Agency was closed June 29, 2012; archival data will be searched using the Canadian Health Research Collection -- archives available on the NAHO website to December 22, 2017)<http://www.naho.ca>Network Environment for Aboriginal Health Research (NEAHR)[http://cahr.uvic.ca/nearbc/elibrary/current-publications/](http://cahr.uvic.ca/nearbc/elibrary/current-publications)BC Centres for Disease Control (Chee Mamuk - Aboriginal Health)<http://www.bccdc.ca/our-services/programs/chee-mamuk-aboriginal-health>First Nations in BC Knowledge Network<http://fnbc.info>First Nations Health Authority<http://www.fnha.ca>/Aboriginal Portal<http://aboriginal.ubc.ca>/Indigenous Affairs Website (Government of Alberta)<http://indigenous.alberta.ca>Ministry of Government Relations (First Nations Metis and Northern Affairs) (Government of Saskatchewan)<https://www.saskatchewan.ca/residents/first-nations-citizens/saskatchewan-first-nations-metis-and-northern-affairs-directory>Centre for Aboriginal Health Research (CAHR)[http://umanitoba.ca/centres/cahr/](http://umanitoba.ca/centres/cahr)First Nations, Metis and Inuit Health (University of Manitoba)[http://umanitoba.ca/faculties/health_sciences/medicine/fnmi_health/](http://umanitoba.ca/faculties/health_sciences/medicine/fnmi_health)Indigenous and Municipal Relations (Government of Manitoba)[https://www.gov.mb.ca/ana/](https://www.gov.mb.ca/ana)Ministry of Indigenous Relations and Reconciliation (Government of Ontario)<https://www.ontario.ca/page/ministry-indigenous-relations-and-reconciliation>Centre for Indigenous Studies (University of Toronto)<http://indigenousstudies.utoronto.ca>Secretariat aux affaires autochtones (Gouvernement de Quebec)<http://www.autochtones.gouv.qc.ca/index_en.asp>Aboriginal Affairs (Government of New Brunswick)<http://www2.gnb.ca/content/gnb/en/departments/aboriginal_affairs.html>Office of Aboriginal Affairs (Government of Nova Scotia)[http://novascotia.ca/abor/office/](http://novascotia.ca/abor/office)Aboriginal Affairs Secretariat (Government of Prince Edward Island)[http://www.gov.pe.ca/aboriginalaffairs/](http://www.gov.pe.ca/aboriginalaffairs)Department of Labrador and Aboriginal Affairs Office (LAAO) (Government of Newfoundland & Labrador)[http://www.laa.gov.nl.ca/laa/](http://www.laa.gov.nl.ca/laa)Aboriginal Relations (Government of Yukon)[http://www.eco.gov.yk.ca/aboriginalrelations/](http://www.eco.gov.yk.ca/aboriginalrelations)NWT Aboriginal Governments<http://www.daair.gov.nt.ca/en/nwt-aboriginal-governments>Aboriginal Affairs and Intergovermental Relations (Government of the North West Territories)<http://www.daair.gov.nt.ca>Department of Executive and Intergovermental Affairs (Aboriginal Affairs) Government of Nunavut<http://www.gov.nu.ca/eia/information/aboriginal-affairs>Population Research and Outcomes Studies Unit (PROS) (University of Melbourne)[https://health.adelaide.edu.au/pros/](https://health.adelaide.edu.au/pros)Aboriginal and Torres Strait Islander-Australian Government Policy and Program Connection Website (Government of Australia -- and State Site Portal)<http://www.indigenous.gov.au>/Australian Institute of Health and Welfare<http://www.aihw.gov.au/publication-detail/?id=10737419754>Australian Policy Online<http://apo.org.au>The Lowitja Institute (Australia's National Institute for Aboriginal and Torres Strait Islander Health Research)<http://www.lowitja.org.au>National Centre for Immunization Research and Surveillance (NCIRS) (Government of Australia)<http://www.ncirs.edu.au>/Immunize Australia<http://www.immunise.health.gov.au>/Toi Te Ora Public Health (Government of New Zealand)[https://www.govt.nz/organisations/toi-te-ora-public-health-service/](https://www.govt.nz/organisations/toi-te-ora-public-health-service)New Zealand Ministry of Health<https://www.health.govt.nz>/US Centers for Disease Control<http://www.cdc.gov>US Indian Health Service (Federal Health Program for American Indians and Alaska Natives)<https://www.ihs.gov>Immunize Canada<https://immunize.ca>/Ministry of Health-BC<http://www2.gov.bc.ca/gov/content/governments/organizational-structure/ministries-organizations/ministries/health>BC Centre for Disease Control<http://www.bccdc.ca>/Immunize BC<http://www.immunizebc.ca>/Alberta Health<http://www.health.alberta.ca>/Alberta Health Services<http://www.albertahealthservices.ca>/Immunize Alberta<http://immunizealberta.ca>/SK Ministry of Health<https://www.saskatchewan.ca/government/government-structure/ministries/health>Manitoba Ministry of Health, Seniors and Active Living[http://www.gov.mb.ca/health/](http://www.gov.mb.ca/health)Ontario Ministry of Health and long-term care[http://www.health.gov.on.ca/en/](http://www.health.gov.on.ca/en)Public Health Ontario<http://www.publichealthontario.ca/en/Pages/default.aspx>Quebec Ministry of Health<http://www.msss.gouv.qc.ca/index.php>Institut national de santé publique du Québec (INSPQ)<https://www.inspq.qc.ca/en>New Brunswick Ministry of Health<http://www2.gnb.ca/content/gnb/en/departments/health.html>Nova Scotia Department of Health and Wellness[https://novascotia.ca/DHW/](https://novascotia.ca/DHW)Nova Scotia Health Authority<http://nshealth.ca>/PEI Health and Wellness<https://www.princeedwardisland.ca/en/topic/health-and-wellness>Health PEI<http://www.healthpei.ca>/Newfoundland and Labrador Department of Health and Community Services[http://www.health.gov.nl.ca/health/](http://www.health.gov.nl.ca/health)Canadian Association for Immunization Research and Evaluation (CAIRE)[http://www.caire.ca/about/](http://www.caire.ca/about)Canadian Center for Vaccinology<http://centerforvaccinology.ca>/Vaccine Evaluation Center<http://vaccineevaluationcenter.ca>/Canadian Immunization Research Network (CIRN)<http://cirnetwork.ca>/Yukon Government Department of Health and Social Services<http://www.hss.gov.yk.ca>/NWT Health and Social Services<http://www.hss.gov.nt.ca>/Nunavut Department of Health<http://www.gov.nu.ca/health>Canadian Public Health Association<http://www.cpha.ca/en/default.aspx>Australian Indigenous Health Info Net<http://www.healthinfonet.ecu.edu.au>/

Preliminary findings {#Sec15}
--------------------

A search of key national and international websites that register, fund, or publish knowledge syntheses failed to locate an existing synthesis to address our review questions. We identified several helpful systematic reviews in the areas of vaccine hesitancy \[[@CR41], [@CR60], [@CR98]\], acceptability \[[@CR60], [@CR99]\], inequity of HPV vaccine uptake \[[@CR100]\], barriers and facilitators to HPV vaccination in young women \[[@CR25], [@CR57], [@CR61], [@CR101], [@CR102]\], and identification and assessment of interventions to improve HPV vaccine uptake \[[@CR64], [@CR79], [@CR80], [@CR103]\]. We identified several tangential emergent syntheses through the PROSPERO International Prospective Register of Systematic Reviews pertaining to parental-reported barriers and facilitators to HPV vaccination \[[@CR104]\], hesitancy toward HPV vaccine \[[@CR105]\], the effects of mass media interventions on enhancing childhood vaccine uptake \[[@CR106]\], health care provider recommendation of HPV vaccine in boys and young men \[[@CR107], [@CR108]\], and individual and environmental-level factors influencing HPV vaccination \[[@CR107]\]. A relevant review of specific subpopulations that included Canadian or global Indigenous peoples was not located. The core database search was conducted in MEDLINE using the Ovid interface, including in-process and e-pub-ahead-of-print records, without restrictions, and generated a total of 2096 citations after de-duplication. A search filter for identifying literature for Canadian Indigenous peoples was added to the core MEDLINE search and feedback from PRESS review integrated \[[@CR109]\].

Study selection {#Sec16}
---------------

Search strategy findings will be cataloged using Endnote™ X8.0 and duplicates removed manually. For inclusion, studies must involve one or more global Indigenous peoples *and* discuss barriers or supports to V/HPV-V *and/or* interventions to increase uptake/acceptability or reduce V/HPV-V hesitancy, as per study eligibility criteria. We will exclude studies that do not: a) involve a global Indigenous population (or a subpopulation comprising ≥ 50% of study participants), b) discuss barriers or supports to V/HPV-V; c) discuss V/HPV-V interventions or interventions that enhance the acceptability or uptake of V/HPV-V or reduce V/HPV-V hesitancy, d) report extractable data, or e) report original research.

Title and abstract screening (Level 1) {#Sec17}
--------------------------------------

Prior to commencing Level 1 (title and abstract) screening \[[@CR89]\], we will calibrate screening among reviewers on a random sample (5% of the total number of citations) \[[@CR83]\]. All citations will then be screened independently and in duplicate by two investigators \[GN/KJM/MSB/NB/SG/CC/RVR\] and discrepancies discussed until consensus is reached or, failing consensus, referred to a third reviewer for final resolution. Overall screening concordance will be calculated using the Kappa statistic \[[@CR110]\]. Only those studies meeting screening inclusion/exclusion criteria will be retrieved for full text Level 2 \[[@CR89]\] review. To pass Level 1 screening, studies must discuss one or more global indigenous peoples *and* barriers or supports to V/HPV-V *or* vaccination interventions to increase acceptability and uptake or reduce hesitancy for V/HPV-V.

Full-text review and data abstraction (Level 2) {#Sec18}
-----------------------------------------------

The anticipated outcomes of interest are barriers and supports to V/HPV-V (qualitative and quantitative data, if measured) and interventions to enhance V/HPV-V acceptability *or* uptake or reduce hesitancy (qualitative and quantitative data, if measured), in Canadian and global Indigenous peoples and, secondarily, in Canadian Indigenous youth (\< 18 years). Where multiple citations occur, data will be combined to create a full description of the study. Should a lack of clarity about multiple citations arise, information will be sought from authors and studies excluded where discrepancies remain unresolved. We will calibrate full text screening among reviewers using the same methods described for Level 1. The full text of each included citation will be reviewed independently and in duplicate by two investigators \[CC/GN/KJM/MSB/NB/SG/SM/RVR/CB\] and discrepancies resolved by a third investigator.

A draft data abstraction tool will be generated in MS Excel \[[@CR111]\], based on the Data Collection Checklist from the Cochrane EPOC \[[@CR112]\]. A subsection of the tool will be developed to assess the included intervention studies, specifically. We will use a set of a priori variables generated from preliminary findings (Table [4](#Tab4){ref-type="table"}), combined with several items adapted from the Community Guide's Data Abstraction Framework (CGDA) \[[@CR113]\] and the Standards for Reporting Implementation Studies Statement (StaRI) \[[@CR114]\]. The abstraction tool will be pilot-tested by reviewers on a random sample of included articles and revised until consensus is reached on key variables and definitions.Table 4Level 2 (full text review) draft data abstraction tool (variables and definitions)VariableDefinitionStudy characteristics RefidStudy unique reference identification number AuthorAuthor last name, initials YearYear of publication TitleFull title of manuscript LanguageOriginal language of publication LocationGeographic location (country) of study TimeData collection period (start to end of recruitment) DataData collection method(s) FundingReported funding source(s) for study PopulationIndigenous population, community or ethnicity, as defined by study authors and eligibility criteria as reported by authors TargetTarget population (health care providers, vaccine recipients, parents, policy makers etc.) Report(s)Source(s) of reported barriers and/or supports NumberNumber of participants in study age_mean, age_sdAge of included participants \[mean (SD), median (IQR), or categorical age, as reported\] age_med, age-iqr age_cat YouthStudy participants (or cohort of study participants) were \< 18 years (Yes = 1, No = 0, Not Reported NR =99) Gender% female Gender_targetFemale, male, female and male ContextDescribe context of implementation (may include a description of the social, economic, policy, healthcare, organizational or other contextual facets that may influence scale implementation) SettingDescribe study setting, as defined by study authors (may include characteristics of the locations, personnel, resources for implementation and/or criteria for eligibility as an implementation site that are used in the study setting_otherDescribe 'other setting', as defined by study authors AimobjStudy aims and objectives DesignStudy design0 = RCT (Randomized controlled trial)1 = NRCT (non-randomized controlled trial)2 = cohort3 = case control4 = controlled before-after5 = interrupted time series6 = qualitative7 = cross-sectional survey8 = scoping, systematic or other synthesis9 = mixed methods10 = other design_otherDescribe 'other study design' SamplingDescribe sampling strategy InclusionStudy inclusion criteria, as reported by study authors ExclusionStudy exclusion criteria, as reported by study authors vaccine_deliveryAgency, authority, or group(s) administering vaccine vaccine_settingThe environment (clinic, school or other) where the vaccine was delivered vaccine_type, vaccine_batchType and/or batch of vaccine administered vaccine_seriesDescribe how the vaccine administered (one dose, 3 doses etc.) vaccine_statusReported vaccination status of study participants (Yes = 1, No = 0) vaccine_statusdescribeIf yes, describe whether full series, or only partial vaccination etc. mod_frameAuthors describe explicitly, a health model, framework or theory utilized to frame their study (Yes = 1, No = 0, Not clear = 99) mod_frame_validDid the researchers use or test the model/framework or theory? (Yes = 1, No = 0, Not reported = 99) mod_framedescribeDescribe model, framework or theory StudylimReported study limitations OnoffresLocation of participants (on reserve, off reserve) onoffres_otherDescribe location of participants if participants are located off reserve GeographyRelative geographic location as reported by study authors SesReported socioeconomic status of participants education_levelReported level of education of participants knowledge_gen\*Reported participant knowledge about vaccination attitudes_gen\*Reported participant attitudes about vaccination beliefs_gen\*Reported participant beliefs about vaccination behaviors_gen\*Reported participant behaviors regarding vaccination knowledge_HPV\*Reported participant knowledge about HPV vaccination attitudes_HPV\*Reported participant attitudes about HPV vaccination beliefs_HPV\*Reported participant beliefs about HPV vaccination behaviors_HPV\*Reported participant behaviors regarding HPV vaccination HPV_awareAwareness of HPV vaccine sex_statusParticipants reporting sexually active pap_statusParticipants reporting prior abnormal pap smear test STI_statusParticipants reporting previous STI HPV_statusParticipants reporting prior HPV infectionBarriers and Supports barrier\*Describe barriers to vaccine (all types)subcategories will be determined inductively barrier_descrDescribe which vaccine type the reported barriers discuss barrier_HPV\*Describe barriers to HPV vaccinesubcategories will be determined inductively support\*Describe supports to vaccine (all types)subcategories will be determined inductively support_descrDescribe which vaccine type the reported supports discuss support_HPV\*Describe supports to HPV vaccinesubcategories will be determined inductively recommend_gen\*Describe study recommendations for vaccination (all types)subcategories will be determined inductively recommend_descrDescribe which vaccine type the recommendations pertain to recommend_HPV\*Describe study recommendations for HPV vaccinationsubcategories will be determined inductivelyVaccine Intervention Outcomes OutcomeimplemDescribe primary and other outcomes of the implementation strategy, and how they were measured OutcomeinterventDescribe primary and other outcomes of the intervention, and how they were measured ProcessDescribe the process evaluation objectives and outcomes related to the mechanism by which the strategy is expected to work Intervention\*Describe vaccine interventionsubcategories will be determined inductively intervention_HPV\*Describe HPV vaccine interventionsubcategories will be determined inductively impleminterventDescribe the implementation strategy HPVimpleminterventDescribe the HPV-specific implementation strategy SubgroupsDescribe any subgroups or nested studies undertaken in the study RRRisk ratios reported RR_pvalueReported p-values for RR OROdds ratios reported OR_pvalueReported *p*-values for OR EconinterventMethods for resource use, costs, economic outcomes and analysis for the intervention EconimplemMethods for resource use, costs, economic outcomes and analysis for the implementation strategy SamplesizeDescribe the sample sizes, calculations AnalysisDescribe analytic methods with rationale for methodological choice SubanalysisDescribe subanalyses, representativeness and outcomes of subgroups including those recruited to specific research tasks FidelimplemFidelity of the implementation strategy as planned and adaptation to suit context and preferences FidelinterventFidelity of delivering the core components of the intervention ContextchangeDescribe contextual changes that may affect outcomes HarmsDescribe all important harms or unintended effects for each group vaccine_acceptanceReported factors influencing vaccine acceptance (study participant attitudes and beliefs) vaccine_uptakeA rate or quantification of the number or proportion of the study population who received vaccine intervention vaccine_refuseA rate or quantification of the number or proportion of the population who refused vaccine intervention vaccine_hesitancyDescribe reported factors relating to under-immunization, delay or questioning of vaccines, selecting only certain vaccines, desire to access a trustworthy healthcare provider \[Specific description of hesitancy as a barrier (all types of vaccine)\] hesitancy_HPVDescribe reported factors relating to under-immunization, delay or questioning of vaccines, selecting only certain vaccines, desire to access a trustworthy healthcare provider \[Specific description of hesitancy as a barrier (HPV vaccination)\] CDGA_ICCGDA Intervention Category \[[@CR142]\] -- Informational, Behavioral, Environmental CGDA_ILCDGA Intervention Intensity Level \[[@CR142]\] -- active engagement to individual, active engagement to population, passive engagement with significant effort, passive engagement with minimal effort InterventimplicDescribe policy, practice or research implications for the intervention, including sustainability ImlemimplicDescribe policy, practice or research implications for the implementation strategy, specifically related to scalability RegulatoryEthics approval, trial/study registration (and protocol if available), governance of data use, presence of conflicts of interest etc.\*denotes subcategories will be generated inductively

Methodological quality {#Sec19}
----------------------

Methodological quality will be assessed using a universal appraisal tool (Quality Assessment Tool for Reviewing Studies with Diverse Designs - QATSDD) developed for the assessment of quality in diverse study designs \[[@CR115]\]. The 4-point tool scoring system will be applied to each item, allowing an overall quality assessment for each study using one set of criteria. Team members will independently pilot the quality assessment tool using two to three included studies. The team will review discrepancies and discuss to consensus at a weekly team meeting before proceeding. Two investigators \[CC/GN/KJM/MSB/NB/SG/SM/RVR/CB\] will assess methodological quality in all included studies, independently and in duplicate. Discrepancies will be noted and discussed until consensus, or failing consensus, referred to a third investigator. Quality scores will be reported as combined reviewer scores across the 16 items and the total score for each study and then summarized and used to fully describe the nature and characteristics of included studies in the analysis. Quality assessment scores will be presented in tabular format for all included studies to highlight the strengths and weaknesses of the evidence base. Quality assessments will be used to 1) describe and characterize the methodological rigor and scientific quality of included studies; and 2) provide context for the interpretation of findings, formulation of conclusions, and/or recommendations arising from the review. Extreme outlier scores will be discussed by the team and depending on the issues identified, may be excluded to avoid the influence of significantly flawed studies on statistical and/or conceptual analyses, as appropriate.

A secondary quality analysis of the included effective intervention studies will be undertaken using the domains of the Consolidated Framework for Implementation Research (CFIR) \[[@CR116]\]. The main purpose of this quality analysis is to gather and assess, where available, detail about the presence and nature of the individual-level factors and contextual, intervention or implementation process factors for implementation, using a robust framework.

Data analysis {#Sec20}
-------------

The overall study flow will be reported using a PRISMA diagram \[[@CR86]\], providing a summary of citation numbers, sources, exclusions/rationale, and final number of included studies. Data analysis of abstracted variables will consist of two main sections with several subsections \[[@CR82]\], including: (1) an inductive, qualitative, thematic synthesis \[[@CR117]\] of all documented barriers and supports and (2) a quantitative analysis of measured barriers and supports found to be statistically significant, summarized as mean proportion and standard deviation of participants reporting the barrier or support (or other relevant aggregate measures as appropriate) or ranked by frequency of reported barriers or supports. The thematic analysis will proceed using a step-wise, iterative approach. Team members will review each study independently, and in duplicate. Line-by-line coding of identified barriers and/or supports will be conducted on each study, and we will note similarities and differences in codes and discuss any discrepancies to consensus at weekly team meetings. Subsequent studies will be subjected to the same analysis, contributing text to existing (or generating new) themes, as appropriate. Once the coding process is complete, the team will review each of the barrier and support themes and sub themes, refine their definitions if necessary, and examine the text within them for consistency, code interrelations and to identify any potential conceptual hierarchies. All changes to codes, conceptual re-alignments, discussions and decisions will be documented as part of the study audit trail. We will report a summary of emerging themes, sub themes, definitions and linkages to studies in which themes arise.

We anticipate the ability to provide both a descriptive synthesis and quantitative summary of relevant measures for interventions; however, recent reviews examining barriers and supports in the area of HPV vaccination revealed a level of heterogeneity among studies precluding meta-analysis \[[@CR25]\]. All included studies describing interventions will be assessed using the Community Guide's Data Abstraction Framework \[[@CR118]\] with interventions categorized and frequencies reported by type and intensity.

We plan to report findings pertaining to Canadian Indigenous and global Indigenous peoples separately, contingent on the volume of eligible literature identified in each group. We will report results for HPV vaccines separately from results arising from studies of other vaccines, given the characteristics and contextual factors associated with HPV compared with other vaccines and target populations. A draft analysis plan and anticipated products of the synthesis are outlined in Table [5](#Tab5){ref-type="table"}.Table 5Draft analysis plan, analytic method, questions to guide analysis and anticipated review outputsReview aimsMethodGuiding questionsAnticipated review outputsPrimary Aims 1: To identify and assess the documented barriers and supports to HPV and other vaccinations in Canadian and global Indigenous peoplesThematic synthesis• What are the documented barriers and supports described in eligible studies?\
• What is the quality of the eligible literature? (QATSDD tool)\
• What, if any, themes arise in the literature describing barriers and supports to vaccine or HPV vaccine in Canadian and global Indigenous peoples?• To describe articles that report barriers and/or supports to HPV and other vaccines\
• To establish the quality of included articles (item and total study scores)\
• To analyze and (where possible) group barriers and facilitators meaningfully across studies\
• To analyze any themes among barriers and supports to vaccine or HPV vaccine that are specific to Canadian Indigenous populations\
• To statistically analyze measured barriers and supports across studies (should they be deemed appropriate for meta-analysis)Quantitative Analysis• What, if any, barriers and supports to vaccine or HPV vaccine in Canadian and global Indigenous peoples are statistically significant? 2: To identify and assess the documented effective interventions to increase acceptability, uptake or reduce hesitancy of vaccination, and HPV vaccination, in Canadian and global Indigenous peoplesDescriptive statistics,\
narrative summary• What interventions are documented to increase vaccine or HPV vaccine acceptability and uptake and reduce hesitancy in Canadian and global Indigenous populations?\
• What is the quality of the eligible literature? (QATSDD tool)\
• What, is the nature of vaccine or HPV acceptability, hesitancy and uptake in Canadian and global Indigenous peoples?• To describe articles that report effective strategies for increasing vaccine or HPV vaccine acceptability, uptake or reducing hesitancy in Canadian and global Indigenous peoples\
• To establish the quality of included articles (item and total study scores)\
• To describe quantitatively and qualitatively (thematic synthesis) the nature and characteristics of interventions to increase vaccine or HPV vaccine acceptability and uptake or reducing hesitancy in Canadian and global Indigenous peoples\
• To synthesize evidence of knowledge, beliefs, and attitudes of Canadian and global Indigenous peoples arising in the eligible literatureDescriptive Analysis• What are the features (e.g. intervention category, definition, intensity level) and CFIR domain/subdomain assessment of each reported intervention?• To describe and systematically assess effective interventions and report findings using the CFIR framework domains/subdomains.Secondary Aims 3: To identify and assess documented barriers and supports to vaccination, and HPV vaccination, in youth (\< 18 years) within Canadian and global Indigenous peoples.Thematic synthesis• What are the documented barriers and supports described in eligible studies for vaccine and HPV vaccine in youth (\< 18 years) within Canadian and global Indigenous peoples?\
• What is the quality of the eligible literature? (QATSDD tool)\
• What, if any, themes arise in the barriers and supports to vaccine or HPV vaccine in youth (\< 18 years) in Canadian and global Indigenous peoples?• To describe articles that report barriers and/or supports to HPV and other vaccines in Canadian and global Indigenous youth (\< 18 years)\
• To establish the quality of included articles\
• To analyze (and where possible) group barriers and facilitators meaningfully across studies\
• To analyze any themes among barriers and supports to vaccine or HPV vaccine that are specific to youth (\< 18 years) in Canadian Indigenous populations\
• Cross-study qualitative synthesis of themes describing barriers and supportsQuantitative Analysis• What, if any, measured barriers and supports to vaccine or HPV vaccine in youth (\< 18 years) in Canadian and global Indigenous peoples are statistically significant?• To statistically analyze measured barriers and supports across studies (descriptive statistics; based on recent systematic reviews it is unlikely that a meta-analysis will be possible) 4: To identify and assess documented interventions to increase acceptability and uptake and reduce hesitancy of vaccination and HPV vaccination in youth (\< 18 years) within Canadian and global Indigenous peoples.Descriptive statistics, thematic summary• What interventions are documented to increase vaccine or HPV vaccine acceptability, uptake and reduce hesitancy in Canadian and global Indigenous youth (\< 18 years)?\
• What is the quality of the eligible literature?\
• What, if any, themes arise in the descriptions of interventions for vaccine or HPV acceptability/hesitancy and uptake in Canadian and global Indigenous youth (\< 18 years)?• To describe articles that report effective strategies for increasing vaccine or HPV vaccine acceptability, uptake or reducing hesitancy in Canadian and global Indigenous peoples\
• To establish the quality of included articles\
• To describe quantitatively (descriptive statistics) and qualitatively (thematic synthesis) the nature and characteristics of interventions to increase vaccine or HPV vaccine acceptability, uptake or reduce hesitancy in Canadian and global Indigenous youth (\< 18 years) (based on recent systematic reviews it is unlikely that a meta-analysis will be possible)\
• To synthesize Canadian and global Indigenous youth (\< 18 years) knowledge, beliefs and attitudes arising in the eligible literature\
• Cross-study qualitative synthesis of themes describing acceptability, uptake and reduced hesitancy interventionsDescriptive Analysis• What are the features (e.g., intervention category, definition, intensity level) and CFIR domain/subdomain assessment of each reported intervention to increase acceptability and uptake, and reduce hesitancy of vaccination and HPV vaccination in youth (\< 18 years) within Canadian and global Indigenous peoples?• To describe and systematically assess interventions to increase acceptability and uptake, and reduce hesitancy of vaccination and HPV vaccination in youth (\< 18 years) within Canadian and global Indigenous peoples, and report findings using the domains/subdomains of the CFIR framework.

Discussion {#Sec21}
==========

To date, we have not located a systematic review describing the barriers and supports to HPV vaccination or one that gathered and assessed effective interventions to increase acceptability and uptake of HPV vaccines in Indigenous peoples. Previous systematic reviews have been limited to vaccine efficacy in Indigenous peoples \[[@CR119]--[@CR121]\]. In addition to identifying studies that describe the barriers and supports to vaccination and interventions to increase vaccination acceptability and uptake in Indigenous peoples, the proposed systematic review will also aim to identify studies that specifically describe the barriers and supports to HPV vaccination and interventions that have been shown to increase acceptability and uptake of the HPV vaccine. While there is some evidence to suggest that tailoring vaccine strategies to the needs and preferences of adolescents using technology interventions may be promising, it is unclear how these findings relate to Canadian Indigenous youth. We have chosen to focus on HPV vaccination because, despite wide-spread availability, uptake of HPV vaccination between Indigenous and non-Indigenous youth remains unequal \[[@CR19]\]. This finding is similar to that found in non-Indigenous populations in the USA where only 65% of girls and 56% of boys initiate a HPV vaccination series and fewer (43% and 32%, respectively) complete the series \[[@CR64]\]. The approach we propose will allow us to synthesize existing evidence of HPV vaccine-specific barriers, supports, and effective interventions that may provide insights into vaccination practices that better meet the needs of Indigenous peoples.

While the importance of multiple \[[@CR79], [@CR80], [@CR122]\] and/or tailored \[[@CR123], [@CR124]\] (versus singular) interventions in some target groups remains a matter of debate in the implementation literature \[[@CR125]\], multiple strategies focused on increasing HPV vaccination rates in non-Indigenous peoples have been shown to be effective \[[@CR80], [@CR126]--[@CR132]\]. Furthermore, interventions tailored to address specific barriers to HPV vaccination or to address contextual differences may be required \[[@CR133], [@CR134]\]. It is unlikely, given the apparent state of the literature, that detailed information is available about contextual influences on HPV vaccination barriers and supports and HPV vaccination acceptability/hesitancy and uptake.

We have chosen to include global Indigenous peoples \[[@CR133], [@CR134]\] and anticipate that this review may suggest that Indigenous peoples, regardless of country, may experience similar barriers and supports to vaccination acceptability/hesitancy and uptake. With this in mind, we chose a broad definition of Indigenous peoples to help generate results that are relevant to many stakeholders. Given the dearth of literature in this area, we will consider all study designs meeting inclusion criteria, without restriction by language, location, or data type. We anticipate only a small number of relevant studies to emerge from the search and, hence, have used a broad, less restrictive search strategy that aims to capture literature related to V/HPV-V among Indigenous peoples.

The results of this study are expected to inform future research, policies, programs, and community-driven initiatives to enhance acceptability and uptake of vaccination among Indigenous peoples. Specifically, this review will identify and describe the documented barriers, supports, and interventions for V/HPV-V. These will provide a foundation to inform the development of new vaccination strategies among Indigenous peoples. We anticipate the review will identify the nature of evidence gaps and highlight areas requiring further study.

Dissemination and knowledge translation plan {#Sec22}
--------------------------------------------

To our knowledge, this study will contribute the first systematic review of the global literature in this area. We will take an integrated knowledge translation \[[@CR135], [@CR136]\] approach to guide our synthesis in close partnership with First Nation knowledge holders and others who will help interpret, structure, and disseminate findings to relevant research, clinical, Indigenous, policy, and decision maker groups. We anticipate there may be important regional, group, and contextual differences present in the data that will require tailored dissemination (EHVINA Study Research Team: Alberta First Nations Health Care Professional Stakeholder Meeting (2015), unpublished; EHVINA Study Research Team: EHVINA study -- Alberta First Nations Elders Gathering (2015), unpublished; EHVINA Study Research Team: Canadian Institutes for Health Research - Institute for Cancer Research Stakeholder Engagement Brainstorming Session (2017), unpublished; EHVINA Study Research Team: Exploring International Collaborative Connections (2016), unpublished) and plan to co-present findings with First Nation partners. We anticipate strong receptivity for study findings and will utilize a translation process that is informed by the Knowledge-to-Action framework \[[@CR137], [@CR138]\] but is deliberately inductive to ensure knowledge systems, contexts, and the unique needs of our knowledge users are considered \[[@CR77]\]. This process will extend from the analysis and interpretation of review findings through the conceptualization, mapping, and execution of vaccination strategies \[[@CR139]--[@CR141]\]. In closing, the intent of this synthesis is to assess the global literature pertaining to barriers and supports to V/HPV-V and identify effective interventions to enhance acceptability and uptake of V/HPV-V, in Canadian and global Indigenous peoples. We anticipate that this synthesis will provide numerous stakeholder groups with a better understanding of the current state of the literature in this area and help inform the development of interventions that encourage V/HPV-V acceptability and uptake and reduce hesitancy in Canadian and global Indigenous peoples.

Additional file
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CDGA

:   Community guide's data abstraction framework (CGDA) (<https://www.thecommunityguide.org/about/our-methodology>)

CFIR

:   Consolidated framework for implementation research

ENTREQ

:   Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ

EPOC

:   Cochrane effective practice and organization of care (epoc.[cochrane.org](http://cochrane.org)/)

FN

:   First nations

HPV

:   Human papilloma virus

KT

:   Knowledge translation

NVivo

:   qualitative data analysis software from QSR international ([www.qsrinternational.com/nvivo/what-is-nvivo](http://www.qsrinternational.com/nvivo/what-is-nvivo))

PRESS

:   Peer review of electronic search strategies: 2015 guideline statement

PROSPERO

:   International prospective register of systematic reviews (<https://www.crd.york.ac.uk/prospero/>)

QATSDD

:   Quality assessment tool for reviewing studies with diverse designs

STaRI

:   Standards for reporting implementation studies statement

STATA

:   Data analysis and statistical software program (<https://www.stata.com>/)

URL

:   Universal resource locator

USA

:   United States of America

V/HPV-V

:   Vaccination and specifically HPV vaccination
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